Antibody Response Following the Intranasal Administration of SARS-CoV-2 Spike Protein-CpG Oligonucleotide Vaccine

Antibody Response Following the Intranasal Administration of SARS-CoV-2 Spike Protein-CpG Oligonucleotide Vaccine

The new coronavirus infection causes severe respiratory failure following respiratory tract infection with severe acute respiratory syndrome-related coronavirus (SARS-CoV-2). All currently approved vaccines are administered intramuscularly; however, intranasal administration enhances mucosal immunit...

Full description

Bibliographic Details
Main Authors: Kentaro Muranishi, Mao Kinoshita, Keita Inoue, Junya Ohara, Toshihito Mihara, Kazuki Sudo, Ken J. Ishii, Teiji Sawa, Hiroyasu Ishikura
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Vaccines
Subjects:
SARS-CoV-2
intranasal administration
mucosal immunity
recombinant protein
CpG-deoxyoligonucleotide
Online Access:https://www.mdpi.com/2076-393X/12/1/5

Internet

https://www.mdpi.com/2076-393X/12/1/5

Similar Items